Skip to content

Pacific Biosciences of California

US · PACB #3373 by market cap
1.63 -0.13 -7.39%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

Price chart

Pre-market 1.70 -3.41%
After-hours 1.63 +0.28%
Overnight 1.72 -2.27%
2.901.111.632026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PACB?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +9.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 17.3% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 28.6% Better than 30%
Operating margin -348.5% Better than 4%
Net margin -341.5% Better than 4%
Return on equity -213.5% Better than 3%
Return on invested capital -57.4% Better than 5%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 20.7% Better than 97%
6-month return 33.6% Better than 91%
12-month return (ex latest month) -5.0% Better than 28%
Distance below 52-week high 52.5% Better than 17%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.1x Better than 87%
Debt to assets 89.6% Better than 2%
Interest coverage -77.5x Better than 6%
Free cash flow / net income 62.8% Better than 18%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 40.0% Better than 21%
Upside to average target 62.0% Better than 73%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -16.84%
1M -16.84%
3M +32.52%
6M +36.97%
YTD -12.83%
1Y -13.30%
3Y -81.00%
5Y -93.84%

Key statistics

Price & volume

Prev close
1.76
Open
1.69
Day range
1.61 - 1.73
Avg price
1.66
Volume
13.69M
Turnover
22.75M
Amplitude
6.82%
52-week range
1.07 - 3.44

Valuation

P/E
-0.90
P/E (TTM)
-3.88
P/B
-8.32
EPS
-1.82
Net profit
-569.53M
Net assets
-61.33M

Share structure

Market cap
510.07M
Float cap
499.22M
Shares out
312.93M
Float shares
306.27M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 24% of range
1.07 3.44

52.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-15.01M net over the window

Short interest

Shares short
53.68M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Pacific Biosciences of California (PACB)?

Pacific Biosciences of California last traded at 1.63. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Pacific Biosciences of California's market cap?

About 510.07M.

What is the P/E ratio of Pacific Biosciences of California?

The trailing twelve-month P/E is -3.88. The Valuation tab shows it against the stock's own five-year range.

Does Pacific Biosciences of California pay a dividend?

Pacific Biosciences of California does not currently pay a regular dividend.

Is Pacific Biosciences of California a buy according to analysts?

The consensus of 5 analysts is a Hold rating, with an average 12-month price target of 2.64, which implies 62.0% upside from the current price. This is not investment advice.

What is Pacific Biosciences of California's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Pacific Biosciences of California a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:52:58 · For reference only, not investment advice and not tailored to your situation.

Pacific Biosciences of California discussion 0 comments

Add a comment